Baseline plasma levels of IL-6, TNF-alpha, hsCRP, and BNP did not significantly correlate with ventricular tachyarrhythmias (11% NSVT, 13% VT/VF) in stable heart failure patients over 5.1 months.
Cohort (n=50)
Do baseline inflammatory biomarkers and BNP predict intermediate-term risk of ventricular tachyarrhythmias in stable HF patients with ICDs?
Plasma levels of IL-6, TNF-alpha, hsCRP, and BNP do not predict intermediate-term ventricular tachyarrhythmias in stable heart failure patients with ICDs.
BACKGROUND: Elevated levels of inflammatory biomarkers and brain natriuretic peptide (BNP) are associated with increased mortality in patients with heart failure (HF). HYPOTHESIS: : The aim of the current study was to assess the correlation between circulating biomarkers and ventricular tachyarrhythmias among patients with HF. METHODS: Blood samples from 50 stable ambulatory HF patients with moderate to severe systolic left ventricular (LV) dysfunction and an implantable cardioverter defibrillator (ICD) were analyzed for interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), high-sensitivity C-reactive protein (hsCRP) and BNP. Thereafter, the patients were followed for a mean period of 152 +/- 44 days, during which ventricular tachyarrhythmias were recorded by the ICDs. RESULTS: Follow-up data were obtained from 47 patients. Of them, 45 (96%) had ischemic cardiomyopathy, 38 (81%) had New York Heart Association class I-II, 43 (91%) were males, and the mean age was 68.6 +/- 11.1 years. During follow-up, 5 patients (11%) had nonsustained ventricular tachycardia (NSVT), 6 patients (13%) had sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) and 36 patients (76%) had no events. The circulating biomarkers' levels upon enrollment were not significantly different between patients who subsequently had NSVT or VT/VF and patients who were free of events. CONCLUSIONS: No correlation was found between plasma levels of IL-6, TNF-alpha, hsCRP and BNP and ventricular arrhythmic events among stable HF patients during an intermediate term follow-up of 5.1 months. Further studies are still required to assess the association between these biomarkers and long-term risk of ventricular tachyarrhythmia.
Konstantino et al. (Wed,) conducted a cohort in Stable Heart Failure (n=50). Inflammatory biomarkers and BNP assessment (IL-6, TNF-alpha, hsCRP, BNP) was evaluated on Ventricular tachyarrhythmias (NSVT, sustained VT, or VF). Baseline plasma levels of IL-6, TNF-alpha, hsCRP, and BNP did not significantly correlate with ventricular tachyarrhythmias (11% NSVT, 13% VT/VF) in stable heart failure patients over 5.1 months.